Effect of Nicorandil, Diltiazem, or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts —A Pilot Randomized Controlled Trial (ASRAB-Pilot): Rationale and Study Protocol
ConclusionThis pilot trial will compare the preliminary effects of nicorandil, diltiazem, and isosorbide mononitrate on angiographic and clinical outcomes in patients who have undergone RA-CABG. Recruitment began in June 2020, and the estimated primary completion date is early 2023. Results of this study will provide much needed information for design of large confirmatory trials on the effectiveness of oral antispastic medications after RA-CABG. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research

BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
This article has been co-authored by a patient with right-sidedBRAFV600E metastatic colorectal cancer (mCRC), his caregiver, and an oncologist. Here the patient and caregiver discuss their personal experiences struggling with cancer, including their fears, expectations, and attitudes as the disease progresses. The oncologist describes how patients withBRAFV600E mCRC are treated and how the management strategy can be balanced to mitigate any side effects. Improved diagnostic techniques and the availability of numerous treatment options, including various chemotherapy schemes and molecular-targeted drugs, can aid rapid imple...
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research

Letter to the Editor Regarding “Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single Agent Pembrolizumab for High-Risk Early-Stage Triple Negative Breast Cancer in the United States”
(Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research

Study on the Relationship Between Differentially Expressed Proteins in Breast Cancer and Lymph Node Metastasis
ConclusionOur study provides a new perspective for the understanding of the role of DEPs (especially CTGF, EphA2, S100A4, and PRDX2) in the development and metastasis of breast cancer. They could become potential diagnostic and prognostic biomarkers and therapeutic targets. (Source: Advances in Therapy)
Source: Advances in Therapy - July 9, 2023 Category: Drugs & Pharmacology Source Type: research

Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US
ConclusionsAboBoNT-A had the lowest injection visit costs across indications. These results are suggestive of real-world resource utilization patterns and costs, and, while helpful in informing insurers ’ BoNT-A management strategies, further research into cost differences is warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - July 7, 2023 Category: Drugs & Pharmacology Source Type: research

Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study
ConclusionsWe clearly demonstrated that the initial FSH dosage for patients with PCOS undergoing IVF/ICSI with the GnRH-ant protocol may be calculated on the basis of the woman ’s BMI and ovarian reserve markers. The nomogram will help guide clinicians in the selection of the most appropriate initial FSH dose in the future. (Source: Advances in Therapy)
Source: Advances in Therapy - July 3, 2023 Category: Drugs & Pharmacology Source Type: research

Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients
ConclusionWe identified factors associated with a humoral response to a COVID-19 mRNA vaccine in KTRs. These findings might help physicians to optimize vaccination in KTRs. (Source: Advances in Therapy)
Source: Advances in Therapy - July 1, 2023 Category: Drugs & Pharmacology Source Type: research

B-Clear Phase  2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection
The objective of the phase 2b study B-Clear is to access the efficacy and safety of bepirovirsen in participants with chronic HBV in fection.MethodsB-Clear is a phase  2b, multicenter, randomized, partial-blind (sponsor/participant-blinded, investigator-unblinded) study in participants with chronic HBV infection receiving stable nucleos(t)ide analogue (On-NA) or not currently receiving NA therapy (Not-on-NA). Eligibility criteria included HBsAg >  100 IU/mL, HBV DNA <  90 IU/mL (On-NA) or>  2000 IU/mL (Not-on-NA), and alanine aminotransferase ≤ 2 × upper limit of normal (ULN; On-NA) or<...
Source: Advances in Therapy - July 1, 2023 Category: Drugs & Pharmacology Source Type: research

Safety, Tolerability, and Pharmacokinetics of Kukoamine  B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
ConclusionSingle and multiple intravenous infusions of KB at a dose range of 0.06 –0.24 mg/kg are safe and tolerable in healthy volunteers.Trial RegistrationClinicalTrials.gov identifier, NCT02690961. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review
ConclusionThe efficacy of all biologics in reducing AAER in patients with severe asthma increases with higher baseline BEC, with varying profiles across individual biologics likely due to differing mechanisms of action. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

Fixed-Dose Combination of Dapagliflozin  + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations
ConclusionTriple FDC of DAPA  + SITA + MET ER tablets once daily was significantly better in achieving glycemic control versus dual combination once daily in patients with type 2 diabetes poorly controlled with metformin without any significant safety concerns.Trial RegistrationCTRI/2021/11/038176, registered on 22 November 2021. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy
ConclusionIn this retrospective study based on claims data, NEPA was associated with lower rates of nausea and vomiting and lower CINV-related HCRU and costs compared to APPA following cisplatin-based chemotherapy. These results complement clinical trial data and published economic models supporting the use of NEPA as a safe, effective, and cost-saving antiemetic for patients undergoing chemotherapy. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
ConclusionClinicians indicated a significantly higher preference for the once-at-bedtime dosing schedule versus twice nightly in selecting oxybate therapies overall and when aiming to improve patient QoL or reduce patient anxiety. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

Roadmap for the Management of Type  2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit
AbstractType  2 diabetes mellitus (T2DM) and hypertension are leading risk factors for death and disability in the Middle East. Both conditions are highly prevalent, underdiagnosed and poorly controlled, highlighting an urgent need for a roadmap to overcome the barriers to optimal glycaemic and blood pressure m anagement in this region. This review provides a summary of the Evidence in Diabetes and Hypertension Summit (EVIDENT) held in September 2022, which discussed current treatment guidelines, unmet clinical needs and strategies to improve treatment outcomes for patients with T2DM and hypertension in th e Middle East. ...
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research

EVELUT ®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
ConclusionIn patients with  symptomatic COPD at low exacerbation risk, treatment can be switched from LABA/ICS to LAMA/LABA without compromising clinical benefit, compared with escalating to LAMA/LABA/ICS. Switching from LABA/ICS to LAMA/LABA can provide symptom relief and improve health status without exposure to the risks associated with ICS.Clinical Trial RegistrationClinicalTrials.gov: NCT03954132. (Source: Advances in Therapy)
Source: Advances in Therapy - June 15, 2023 Category: Drugs & Pharmacology Source Type: research